1-Stearoyl-rac-glycerol-d40 (Synonyms: 18:0-d40-MG, 1-Monostearin-d40, MG(18:0-d40/0:0/0:0)) |
カタログ番号GC46499
One-Click Copy Product Info
|
多様な生物学的活性を持つ神経ペプチド
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2692624-09-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
1-Stearoyl-rac-glycerol-d40 is intended for use as an internal standard for the quantification of 1-stearoyl-rac-glycerol by GC- or LC-MS. 1-Stearoyl-rac-glycerol is a monoacylglycerol that contains stearic acid at the sn-1 position. 1-Stearoyl-rac-glycerol levels are decreased in tumor tissue in a mouse model of azoxymethane-induced colorectal carcinogenesis.1 Levels of 1-stearoyl-rac-glycerol are decreased in lung tissue from patients with adenocarcinoma, but are increased in the serum of patients with Buruli ulcer and in the cerebrospinal fluid of patients with the inflammatory demyelinating diseases multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and idiopathic transverse myelitis (ITM).2,3,4 1-Stearoyl-rac-glycerol has been used in the composition of transfersomes for transdermal delivery of doxorubicin in rats, leading to doxorubicin accumulation in lymph nodes, spleen, and heart.5
1.Montrose, D.C., Zhou, X.K., Kopelovich, L., et al.Metabolic profiling, a noninvasive approach for the detection of experimental colorectal neoplasiaCancer Prev. Res. (Phila).5(12)1358-1367(2012) 2.Wikoff, W.R., Grapov, D., Fahrmann, J.F., et al.Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinomaCancer Prev. Res. (Phila).8(5)410-418(2015) 3.Niang, F., Sarfo, F.S., Frimpong, M., et al.Metabolomic profiles delineate mycolactone signature in Buruli ulcer diseaseSci. Rep.5:17693(2015) 4.Park, S.J., Jeong, I.H., Kong, B.S., et al.Disease type- and status-specific alteration of CSF metabolome coordinated with clinical parameters in inflammatory demyelinating diseases of CNSPLoS One11(11)e0166277(2016) 5.Kong, M., Hou, L., Wang, J., et al.Enhanced transdermal lymphatic drug delivery of hyaluronic acid modified transfersomes for tumor metastasis therapyChem. Commun. (Camb.)51(8)1453-1456(2015)
| Cas No. | 2692624-09-0 | SDF | |
| 同義語 | 18:0-d40-MG, 1-Monostearin-d40, MG(18:0-d40/0:0/0:0) | ||
| Canonical SMILES | O=C(C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])OC([2H])([2H])C(O)([2H])C([2H])([2H])O | ||
| Formula | C21H2D40O4 | M.Wt | 398.8 |
| 溶解度 | Chloroform: 50 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.5075 mL | 12.5376 mL | 25.0752 mL |
| 5 mM | 501.5 μL | 2.5075 mL | 5.015 mL |
| 10 mM | 250.8 μL | 1.2538 mL | 2.5075 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 16 reference(s) in Google Scholar.)